1. Baseline characteristics for patients with diabetes in ASCOT-LLA Part I
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

2. Baseline characteristics for patients with diabetes in ASCOT-LLA Part II
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

3. Plasma lipid concentrations (mmol/ l) by visit and treatment (diabetic patients only)
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

4. Cumulative incidence for total cardiovascular events and procedures among diabetic participants in ASCOT-LLA
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

5. Effect of atorvastatin and placebo on cardiovascular (CV) and coronary end points by diabetic status in ASCOT-LLA
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

6. HR by subgroups (diabetic patients only) for total cardiovascular events and procedures
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

7. HR for end points included in total cardiovascular events and procedures (diabetic patients only)
P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157